Wed: Teva jumps but TASE continues to lose ground
Globes reports the Tel Aviv Stock Exchange fell on July 29, with the Tel Aviv 35 down 0.99% and Tel Aviv 125 down 0.96%. Teva Pharmaceutical (NYSE: TEVA; TASE: TEVA) rose 10.17% after Q2 results and raised revenue guidance. Other movers included Enlight Renewable Energy, Elbit Systems, and banks such as Bank Leumi and Hapoalim.
How this was made

The 30-second read
Why it matters
Teva’s raised revenue guidance is the only explicitly described company-specific fundamental driver, making it the primary tradable signal. Other large movers are reported without disclosed catalysts, reducing conviction.
Market read
For traders, the actionable edge is Teva’s guidance-driven repricing amid a broadly weaker TASE tape.
What to watch
The article does not provide the magnitude or specifics of Teva’s raised guidance, nor does it explain the catalysts for other movers, so follow-through risk is elevated.
Background
The piece is a Tel Aviv market wrap with index declines, sector weakness, and a standout Teva earnings and guidance catalyst.
Ticker impact
Teva led the Tel Aviv 35 Index, up 10.17%, after reporting Q2 results and raising revenue guidance.
Bullish bias for the next few sessions as traders digest the raised revenue guidance; watch for follow-through vs mean reversion.
The article attributes the 10.17% jump directly to Q2 results and raised revenue guidance, which is a concrete catalyst for repricing.
Nice rose 5.79% on the day, contributing to the Tel Aviv 35 Index’s strongest movers alongside Teva.
Short-term positive drift is possible, but conviction is limited without a disclosed fundamental driver.
No earnings, guidance, deal, or other primary event is described for Nice in the text.
Enlight Renewable Energy fell 4.79%, the biggest decliner on the Tel Aviv 35 Index, during a broadly weaker market.
Near-term downside pressure could persist if selling is momentum-driven, but fundamentals are unclear from this text.
The body lists the percentage move without any specific news catalyst for ENLT.
Elbit Systems fell 4.30% on the day, among the notable decliners on the Tel Aviv 35 Index.
Potential for continued volatility, but directional conviction is low without a catalyst.
The text only states the percentage move and does not mention earnings, guidance, contracts, or other events for Elbit.
Nova Ltd. dropped 3.91% on the day, listed as one of the notable losers on the Tel Aviv 35 Index.
Watch for follow-through only if broader risk-off persists; company-specific signal is weak.
No discrete NVMI-specific catalyst is provided beyond the decline.
Market effects
Technology index down 2% and banking down 1.5% suggest risk-off pressure, which can amplify dispersion around idiosyncratic earnings/guidance winners like Teva.
Tel Aviv indices broadly lower, implying traders may be reallocating within Israel equities rather than adding net risk.
Limited direct global linkage in the text; the main global read-through is Teva’s guidance affecting sentiment toward pharma earnings season.
Counterpoint
Teva’s +10% move may partially reflect positioning and could mean higher near-term volatility rather than a durable trend if the guidance details are already anticipated.
Key entities
- companyTeva Pharmaceutical Industries Ltd.
Reported Q2 results and raised revenue guidance, driving a +10.17% jump and highest turnover on the Tel Aviv 35 Index.
- companyNice
Reported as up 5.79% on the day, but no specific catalyst is described in the text.
- companyEnlight Renewable Energy
Reported as down 4.79%, with no catalyst provided in the text.



